重组人血管内皮抑制素注射液联合顺铂胸腔灌注治疗肺癌恶性胸腔积液的效果及对免疫球蛋白的影响  

Effect of Recombinant Human Vascular Endothelial Inhibitor Injection Combined with Cisplatin Thoracic Perfusion in the Treatment of Malignant Pleural Effusion in Lung Cancer and Its Influence on Immunoglobulins

作　　者：王悦 WANG Yue(Civil Aviation General Hospital,Beijing 100123,China)

机构地区：[1]民航总医院,北京100123

出　　处：《中国医学创新》2023年第12期5-9,共5页Medical Innovation of China

摘　　要：目的:探讨重组人血管内皮抑制素注射液联合顺铂胸腔灌注治疗肺癌恶性胸腔积液的效果及对免疫球蛋白的影响。方法:选取2019年1月-2020年1月民航总医院收治的94例肺癌恶性胸腔积液患者,按照其治疗方法的异同将其分组,将接受重组人血管内皮抑制素注射液联合顺铂胸腔灌注治疗的患者划分为观察组(n=47),将接受单纯顺铂胸腔灌注治疗的患者划分为对照组(n=47)。比较两组患者的治疗有效率、疾病控制率、生存质量评分、血清相关指标及免疫球蛋白指标。结果:观察组的治疗有效率及疾病控制率均高于对照组(P<0.05)。治疗前,两组各维度生存质量评分比较,差异均无统计学意义(P>0.05);治疗21 d,两组各维度生存质量评分均高于治疗前,且观察组均高于对照组(P<0.05)。治疗前,两组缺氧诱导因子-1α(HIF-1α)、血管内皮生长因子(VEGF)、M2型丙酮酸激酶(PKM2)水平比较,差异均无统计学意义(P>0.05);治疗21 d,两组HIF-1α、VEGF、PKM2均低于治疗前,且观察组均低于对照组(P<0.05)。治疗前,两组的免疫球蛋白A(IgA)、免疫球蛋白G(IgG)及免疫球蛋白M(IgM)比较,差异均无统计学意义(P>0.05);治疗21 d,两组IgA、IgG、IgM均高于治疗前,且观察组均高于对照组(P<0.05)。结论:重组人血管内皮抑制素注射液联合顺铂胸腔灌注治疗肺癌恶性胸腔积液可改善患者免疫状态,提高其生存质量,综合效果显著。Objective:To investigate the effect of Recombinant Human Vascular Endothelial Inhibitor Injection combined with Cisplatin thoracic perfusion in the treatment of malignant pleural effusion in lung cancer and its influence on immunoglobulin.Method:A total of 94 patients with malignant pleural effusion in lung cancer admitted to Civil Aviation General Hospital from January 2019 to January 2020 were selected and grouped according to the similarity and difference of their treatment methods,patients who received Recombinant Human Vascular Endothelial Inhibitor Injection combined with Cisplatin thoracic perfusion were classified as the observation group(n=47),and patients who received Cisplatin alone thoracic perfusion were classified as the control group(n=47).The treatment efficiency,disease control rate,survival quality scores,serum-related indexes and immunoglobulin indexes of the two groups were compared.Result:The treatment effective rate and disease control rate of observation group were higher than those of control group(P<0.05).Before treatment,there were no significant differences in quality of life scores of all dimensions between the two groups(P>0.05);after 21 d of treatment,quality of life scores of all dimensions of both groups were higher than those before treatment,those of the observation group were higher than those of the control group(P<0.05).Before treatment,there were no significant differences in the levels of hypoxia-inducible factor-1α(HIF-1α),vascular endothelial growth factor(VEGF)and pyruvate kinase M2(PKM2)between the two groups(P>0.05);after 21 d of treatment,HIF-1α,VEGF and PKM2 of both groups were lower than those before treatment,those of observation group were lower than those of control group(P<0.05).Before treatment,there were no significant differences in immunoglobulin A(IgA),immunoglobulin G(IgG)and immunoglobulin M(IgM)between the two groups(P>0.05);after 21 d of treatment,IgA,IgG and IgM of both groups were higher than those before treatment,those of observation group were hi

关 键 词：重组人血管内皮抑制素注射液 胸腔灌注 肺癌 恶性胸腔积液 

分 类 号：R734.2[医药卫生—肿瘤]